anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Plantar warts, or verruca plantaris, are common cutaneous lesions of the plantar surface caused by the human papilloma virus (HPV) infection. Current treatments include salicylic acid, cryotherapy, bleomycin, and immunotherapy; however, they have limitations of low-cure rates or side effects. Plantar warts treated with bee venom (BV) have not been reported. Here we present a case of a patient who showed complete remission of multiple plantar warts after BV treatment.
CASE PRESENTATION: A 13-year-old boy experienced total of 16 plantar warts and visited department of dermatology of Korean Medicine. BV was injected into wart sites. Warts were completely removed at the end of the 8-week treatment with no adverse event recorded. There was improvement during the follow-up after 4 weeks.
CONCLUSION: This is the first case of plantar warts that improved with BV injection. This study suggests that BV may be a therapeutic option for individuals who cannot receive cryotherapy due to pain during and after treatment or who have refractory or relapsed warts.
This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have brief sessions (15-30 mins) at the end of week 1, week 4, week 12 and at 6 months.
FIELD: hair coloring. SUBSTANCE: composition for direct coloring of man's hair contains direct cation color not containing oxydases or oxyreductases in suitable for coloring medium. The composition also includes polyol and/or simple ether of polyol. The invention deals with method of hair coloring and packaging of set for coloring composition. EFFECT: steady hair coloring. 20 cl, 2 ex
BACKGROUND: The response to cognitive behavioral therapy (CBT) for chronic fatigue syndrome (CFS) varies greatly between patients, but predictors of treatment success remain to be elucidated. We aimed to identify patient subgroups based on fatigue trajectory during CBT, identify pre-treatment predictors of subgroup membership, and disentangle the direction of predictor - outcome relationships over time.
METHODS: 297 individuals with CFS were enrolled in a standardized CBT program consisting of 17 sessions, with session timing variable between participants. Self-reported levels of fatigue, depressive, anxiety, and somatic symptoms, perceived stress, and positive affect were collected pre-treatment, and after 3, 10, and 15 sessions. Latent Class Growth Analysis (LCGA) was used to identify subgroups based on fatigue trajectories and baseline predictors of group membership. Cross-lagged structural equation models were used to disentangle predictor-outcome relationships.
RESULTS: LCGA identified four fatigue trajectory subgroups, which were labelled as "no improvement" (23 %), "weak improvement" (45 %), "moderate improvement" (23 %), and "strong improvement" (9 %) classes. Higher pre-treatment levels of depressive, anxiety, and somatic symptoms, stress, and lower levels of positive affect predicted membership of the "no improvement" subgroup. Reductions in anxiety preceded reductions in fatigue, while the depressive symptoms - fatigue relationship was bidirectional.
CONCLUSIONS: On a group level, there were statistically significant reductions in fatigue after 15 sessions of CBT, with important individual differences in treatment response. Higher pre-treatment levels of anxious, depressive, and somatic symptoms and perceived stress are predictors of lack of response, with reductions in anxiety and stress preceding improvements in fatigue.
Techniques for executing transient care plans are provided. A transient care plan to be executed via the I/O device is created based on analysis of an initial care plan of a user and a user dataset captured by an I/O device. The initial care plan is a health regimen uniquely determined for the user indicating medical instructions defined with respect to a first frequency. The transient care plan defines a second frequency at which instructions to perform the user activity are to be projected via the I/O device. The transient care plan is executed by projecting the instructions based on the second frequency. The transient care plan is modified based on a change in status of the user to define a third frequency. The modified transient care plan is executed by projecting the instructions to perform the user activity via the I/O device based on the third frequency.
Study drug, erlotinib, is administered along with neoadjuvant chemotherapy. Adjuvant therapy given at discretion of treating physician. Once adjuvant therapy is completed, all patients will receive erlotinib 150 mg daily for 1 year.
The invention provides a pseudo-rabies virus LA-A strain and the establishing method and application thereof and belongs to the field of vaccines in animal medicine. The pseudo-rabies virus LA-A strain is obtained after gE genes are deleted from a pseudo-rabies virus AH02LA strain. The preservation register number of the pseudo-rabies virus AH02LA strain is CGMCC No. 10891. The invention further discloses the establishing method of the LA-A strain and a vaccine with the LA-A strain as the active constituent. The establishing method is simple and can be well adapted to BHK-21 cells, and growing titer is as high as 109.5TCID50/mL. By the adoption of the vaccine containing the pseudo-rabies virus LA-A strain, a pseudo-rabies virus variant strain can be completely protected, and the vaccine not only can prevent morbidity but also can prevent toxin expelling.
The invention belongs to the biomedical technology, and in particular relates to siRNA, shRNA and a recombinant expression vector for specifically inhibiting the expression of a Lamtor5 gene and application thereof. According to the invention, nucleic acid small molecules capable of regulating CH25H and inhibiting syncytia formation are obtained by designing specific siRNA or shRNA targeted by Lamtor5. The siRNA sequence has a positive antisense strand shown as SEQ ID NO.1 and SEQ ID NO. 2; the shRNA sequence has a positive and an negative strand shown as SEQ ID NO.3 and SEQ ID NO. 4. The siRNAs and the shRNAs have good biological activity, can prevent invasion of new coronaviruses and transmission of the new coronaviruses among cells by regulating cell membrane cholesterol distribution and virus-host cell membrane fusion, can inhibit infection of influenza viruses, have the advantages of high yield, low cost, good functionality and the like, and have the potential of being developed into medicines for resisting the new coronaviruses and other respiratory tract enveloped viruses.
Salmonella enteric  serotype Typhimurium is a causative agent for gastroenteritis. It is the leading cause of hospitalization and death caused by a food-borne pathogen in the US. As is the case with many gram- negative pathogens,  Salmonella  spp. use type III secretion systems (T3SS) to deliver proteins to host cells to induce infections. The T3SS uses a molecular syringe and needle, the type III secretion apparatus (T3SA), as a conduit for the transport of the T3SS proteins from the bacteria to the host. Because proteins associated with the tip of the T3SA are extracellular, they are potential protective subunit vaccine candidates against  Salmonella . These pathogens also have a T3SS that is involved with intracellular escape from the vacuole with an associated T3SA. Within this invention, we begin to show proof of concept that these proteins are protective.
Patients with recurrent malignant glioma will receive Nanoliposomal CPT-11 at the time of relapse. The dose will be adjusted according to a phase-1 dose escalation scheme. Patients will receive drug intravenously every 3 weeks until tumor progression or excessive toxicity. Weekly follow up will occur to assess toxicities during the DLT phase of the trial. Patients will have different dose escalation if UGT1A1 is 6/6 versus UGT1A1 is 6/7. Patients with UGT 1A1 of 7/7 will not be eligible. All patients must have UGT 1A1 status know as an eligibility requirement. Patients will be followed for both toxicity and progression, and progression will be evaluated by MR imaging every 6 weeks. Pharmacokinetics will be obtained in the first treatment cycle.
The invention relates to a traditional Chinese medicine formula for treating pinkeye. The formula is prepared from the following active ingredient by weight: 3-5 live earthworms. The live earthworms are washed and put in a clean bowl, 15g of white sugar is added and the liquid is dripped into the eyes after the earthworms are dissolved into water. 2-3 drops are dripped each time and are dripped 3-5 times every day. When being used for children, the formula can be diluted with cold boiled water. The earthworms are salty and cold and have effects on liver, spleen and lung channels. The formula has the functions of clearing heat and calming the liver and has certain curative effects on pinkeye.
This is a single center, blinded, randomized control clinical trial to evaluate the effects of inhaled nitric oxide on the outcome of survival and incidence of bronchopulmonary dysplasia. This trial has a planned enrollment of 138 infants with 68 infants with delayed pulmonary transition assigned to either the treatment or placebo group. There is no enrollment restriction based on gender, ethnicity, or race. Enrollment is expected to take 36 months with an additional 12 months for data analysis.Infants with early pulmonary hypertension will be randomized to the treatment or placebo group. Treatment will continue until resolution of pulmonary hypertension or through Day 14, whichever comes first. Serial echocardiograms will be performed every 48 hours +/-12 hours until Day 14. Oxygen saturation levels will be averaged every 24 hour period following enrollment. This study will provide evidence for the beneficial effects of early diagnosis and treatment of pulmonary hypertension in preterm infants.
Participants will be treated with commercially available Esperoct for a total study duration of 24 months according to the local label and local routine clinical practice at the discretion of the physician. The decision to switch to Esperoct will be made prior to and separate from the decision to enrol in the study.
Schizophrenia is a major public health problem associated with core motivational deficits that are amongst the strongest predictors of impaired functional outcomes. Without motivation, people are unable to maintain their pursuit of employment or educational goals, engage in treatment, and regularly participate in healthy life decisions. Current pharmacological and psychosocial treatments for schizophrenia have demonstrated limited effectiveness for improving this core symptom. Motivation Skills Training (MST) is a novel intervention that addresses this clinical need. The premise of MST is that knowledge about one's level and sources of motivation underlies the ability to regulate (i.e., understand and manage) motivation, and that motivation self-regulation can in turn facilitate task initiation and persistence. By facilitating goal-directed behavior, MST aims to enhance daily functioning and goal attainment in people with schizophrenia. MST teaches people about motivation and how to self-regulate motivation, empowering individuals to become active agents in controlling their own motivation and behavior. This study uses a 2-phase model of intervention testing to establish the feasibility, acceptability and pilot effectiveness of MST for adults ages 18-65 with a schizophrenia spectrum diagnosis. An initial open trial of MST in one outpatient clinic will provide stakeholder input on the acceptability and clinical utility of MST content and format, informing refinements to the treatment manual. A subsequent randomized controlled trial will test the effectiveness of MST versus a Healthy Behaviors Control (HBC) group, both conducted in the context of routine recovery-oriented services.
Patients assigned to the EMERALD group will be invited to join the multi-component program which will last for 1 year. This program will be held on a 4-weekly basis for the first 3-4 months followed by a maintenance program involving 2-4 group activities every year. Between clinic visits, patients in this group will also receive telephone reminders from the staff and peer supporters to reinforce compliance and for social support.
A total of 400 consecutive patients undergoing unsedated colonoscopy as a part of a national colorectal cancer screening program will be randomly assigned to innovative or conventional examination. Randomization will be based on computer-generated randomization lists. All patients will be blinded so they will not know which techniques will be used to assess lesions found in colon. In innovative colonoscopy group narrow band imaging (NBI) and Dual Focus (DF) function will be used to identify and classify all lesions according. to Kudo and NICE classification. Endoscopic biopsy samples will be taken from all lesions and in vivo endoscopic diagnosis will be compared with final histopathological result. Thus, sensitivity, specificity, diagnostic accuracy, predictive values, likelihood ratio and Youden index will be calculated. As secondary endpoints total examination time, cecal intubation rate and pain intensity (VAS) will be determined. This study will help to establish whether advanced imaging technologies used during colonoscopy may improve diagnostic possibilities and whether they prolong examination time or lead to increase of pain intensity afterwards.
<P>PROBLEM TO BE SOLVED: To obtain an adhesive antimicrobial sheet that contains a volatile antimicrobial agent in an adhesive layer and exhibits antimicrobial action not only on the surface of an attached part but also on a space in the vicinity of the attached part and to provide an antimicrobial method using the sheet.  <P>SOLUTION: The adhesive antimicrobial sheet comprises the nonaqueous adhesive layer containing the volatile antimicrobial agent formed on one side of a substrate and has at least 1,000 g/m<SP>2</SP>×24 hrs permeability of the whole sheet. A nonwoven fabric or a porous plastic sheet is preferable as the substrate. In the case of a non-porous plastic sheet, a polyurethane-based resin or a polyamide-based resin is preferably used. Hinokitiol is preferable as the volatile antimicrobial agent. Its inclusion compound is also used. An acrylic adhesive obtained by polymerizing a (meth)acrylic acid alkyl ester as a main component is preferably used as the adhesive.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Circular RNA (circRNA) is thought to mediate the occurrence and development of human cancer and usually acts as a tiny RNA (miRNA) sponge to regulate downstream gene expression. However, it is not clear whether and how circACVR2A (hsa_circ_0001073) is involved in the progression of HCC. The purpose of this study is to clarify the potential role and molecular mechanism of circACVR2A in regulating the progression of hepatocellular carcinoma cells (HCC). The abundance of related proteins in circACVR2A, microRNA (miR511-5p) and PI3K-Akt signaling pathway was determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) or Western blotting. Cell viability, invasion and apoptosis were analyzed by CCK-8, Transwell analysis and Tunel staining, respectively. The interaction between circACVR2A and microRNA was evaluated by double luciferase reporter gene assay. The results showed that circACVR2A was highly expressed in hepatocellular carcinoma cell lines. Our in vivo and in vitro data showed that circACVR2A promoted the proliferation, migration and invasion of HCC. In terms of mechanism, we found that circACVR2A can directly interact with miR511-5p and act as a miRNA sponge to regulate the expression of related proteins in PI3K-Akt signaling pathway.In HCC, circACVR2A can mediate miR-511-5p/mRNA network to activate PI3K signal pathway. This shows that the molecular regulatory network with circACVR2A as the core is a new potential target for diagnosis and treatment of hepatocellular carcinoma.
UNLABELLED: This study evaluated how Apert hand syndactyly presentations and reconstructive techniques influence reconstruction outcomes. All cases at a major paediatric hospital between 2007 and 2022 were analysed, including 98 web space reconstructions in 17 patients. Overall, 62% of hands developed complications and 15% required revision surgery. Upton hand type was significantly associated with postoperative complication incidence, specifically including range-of-motion deficits, flexion contracture, web creep and revision surgery. More severe syndactylies may benefit from additional measures to reduce complications. Rectangular commissural flaps showed 1.9 times greater complication risk than interdigitating triangular flaps, including 11.2 times greater risk of web creep. Zigzag volar finger flaps showed 1.8 times greater complication risk than straight-line incisions, including 3.8 times greater risk of web creep. Our study showed that interdigitating triangular commissural flaps and straight-line volar finger incisions are preferable to rectangular commissural and zigzag finger flaps in most cases of Apert hand syndactyly to minimize complications.
LEVEL OF EVIDENCE: III.
A system including a set of software based Explorers, and a computer assisted methodology support the development of new medical interventions for diseases. The system includes Explorer modules for discovering proposed interventions, designing clinical trials, performing pharmacoeconomic analysis, and illustrating disease progression for various patients over time including creating disease progression tutorials for patients. The Explorers support a bottom-up or data driven methodology that enables a user, such as medical researcher, to mine data sources of clinical, biologic, expert or other types of data to discover, test, evaluate and understand a proposed intervention and its impact on disease progression in different patient types. A Target Discovery Explorer assists the user in identifying leverage points in disease progression in relationship to various patient attributes and interventions, thereby identifying a proposed intervention for the disease. A Clinical Trials Explorer assists the user in designing clinical trials based through identification of combinations of patient attributes and intervention attributes that yield efficacious changes in selected disease progression measures. A Pharmacoeconomic Explorer enables the user to determine relative costs-benefits of a proposed intervention for patients, practitioners, and payers, including quality of life results for patients, pratice results for practitioners, and financial payment results for payers. A Disease Progression Explorer enables the user to visually project disease progression for specified patient attributes and interventions, in order to better understand and explain the effects of an intervention on a disease for such patients and their practitioners, and to select disease progression tutorials that are directed to the specific patient attributes and their corresponding effect on disease progression over time.
BACKGROUND: Massive neurocysticercosis is a rare form of neurocysticercosis, and can lead to serious conditions and even death.
CASE PRESENTATION: Here we present a case of ten-year-old Tibetan girl who developed headache and vomiting. Her brain magnetic resonance imaging (MRI) illustrated lots of intracranial cystic lesions, and no obvious extracranial lesions were found. Serum immunoglobulin G antibodies against cysticerci were positive by the use of an enzyme-linked immunosorbent assay (ELISA). These results in combination with her medical history were in line with massive neurocysticercosis. The patients recovered well after supportive management and antiparasitic treatment.
CONCLUSIONS: This case provides insights on the diagnosis and treatment of massive neurocysticercosis. The treatment of patients with massive neurocysticercosis should be in an individualized fashion, and the use of antiparasitic drugs in these patients must be decided after carefully weighing the risks and benefits.
PURPOSE: To obtain an antimicrobial agent useful for medicine, cosmetic, food, industrial article, household article, having high safety, showing excellently antimicrobial effect to various microorganisms, comprising an extract prepared from a plant of the genus Murraya. CONSTITUTION: The whole plant or one or more parts of leaf, stem, underground stem and fruit of a plant of the genus Murraya are primarily extracted with a polar solvent. Then, the solvent is distilled away from the primary extracted solution and the prepared extract is secondarily extracted with a polar solvent further to give a secondary extract. In the secondary extraction, the extract is washed with water or steam before or after the extraction treatment to give the extract of the plant of the genus Murraya. Then, the prepared extract is used as an essential component to give the antimicrobial agent. The extract contains especially a carbazole compound of formula I and/or formula II. The extract contains preferably about 1-50% of the carbazole compound so as to sufficiently show effects as antimicrobial agent.  By the method, an active ingredient for the antimicrobial agent can be produced in a high purity, simply and efficiently.
The diverse beneficial effects of adiponectin-receptor signaling, including its impact on the regulation of inflammatory processes in vivo, have resulted in development of adiponectin receptor agonists as a treatment for metabolic disorders. However, there are no established non-invasive bioassays for detection of adiponectin target engagement in humans or animal models. Here, we designed an assay using small amounts of blood to assess adiponectin action. Specifically, we tested effects of the small 10-amino acid peptide adiponectin receptor agonist, ALY688, in a sublethal LPS endotoxemia model in mice. LPS-induced pro-inflammatory cytokine levels in serum were significantly reduced in mice treated with ALY688, assessed via multiplex ELISA in flow cytometry. Furthermore, ALY688 alone significantly induced TGF-β release in serum 1 h after treatment and was elevated for up to 24 h. Additionally, using a flow-cytometry panel for detection of changes in circulating immune cell phenotypes, we observed a significant increase in absolute T cell counts in mice after ALY688 treatment. To assess changes in intracellular signaling effectors downstream of adiponectin, phospho-flow cytometry was conducted. There was a significant increase in phosphorylation of AMPK and p38-MAPK in mice after ALY688 treatment. We then used human donor immune cells (PBMCs) treated with ALY688 ex vivo and observed elevation of AMPK and p38-MAPK phosphorylation from baseline in response to ALY688. Together, these results indicate we can detect adiponectin action on immune cells in vivo by assessing adiponectin signaling pathway for AMPK and p38-MAPK, as well as pro-inflammatory cytokine levels. This new approach provides a blood-based bioassay for screening adiponectin action.